S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
NASDAQ:NVUS

Novus Therapeutics (NVUS) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$1.24
$1.41
50-Day Range
$9.85
$16.50
52-Week Range
$4.50
$27.32
Volume
136,436 shs
Average Volume
78,851 shs
Market Capitalization
$1.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NVUS stock logo

About Novus Therapeutics (NASDAQ:NVUS) Stock

Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.


NVUS Stock News Headlines

Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
East Career Technical Academy
Las Vegas Academy of the Arts
Perspective Therapeutics Inc
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Is Novus Therapeutics (NVUS) A Good Stock To Buy Now?
Novus Therapeutics EPS misses by $3.76
Why Novus Therapeutics Is Trading Higher Today
Novus Therapeutics rallies on Anelixis Therapeutics buy
Novus Therapeutics Inc Registered Shs - Profile
Why Novus Therapeutics Is Trading Lower Today
See More Headlines
Receive NVUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NVUS Company Calendar

Last Earnings
11/16/2020
Today
10/01/2023

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NVUS
Fax
N/A
Employees
7
Year Founded
N/A

Profitability

Net Income
$-16,010,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$13.13 per share

Miscellaneous

Free Float
N/A
Market Cap
$1.97 million
Optionable
Not Optionable
Beta
2.07
10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Jon S. Kuwahara CPA (Age 55)
    CPA, SVP of Fin. & Admin., Principal Financial Officer and Principal Accounting Officer
    Comp: $295.72k
  • Mr. Gregory J. Flesher (Age 50)
    Consultant
    Comp: $482.13k
  • Dr. David-Alexandre C. Gros M.D. (Age 48)
    CEO & Non Independent Director
  • Dr. Steven N. Perrin Ph.D. (Age 55)
    Pres, Chief Scientific Officer & Non Independent Director













NVUS Stock - Frequently Asked Questions

How were Novus Therapeutics' earnings last quarter?

Novus Therapeutics, Inc. (NASDAQ:NVUS) released its quarterly earnings results on Monday, November, 16th. The biopharmaceutical company reported ($5.51) EPS for the quarter, missing the consensus estimate of ($1.64) by $3.87.
Read the conference call transcript
.

When did Novus Therapeutics' stock split?

Shares of Novus Therapeutics reverse split on Monday, October 5th 2020. The 1-18 reverse split was announced on Friday, October 2nd 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 2nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of Novus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novus Therapeutics investors own include Tonix Pharmaceuticals (TNXP), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), CymaBay Therapeutics (CBAY), Novavax (NVAX), Geron (GERN), Inovio Pharmaceuticals (INO), Verastem (VSTM) and vTv Therapeutics (VTVT).

What is Novus Therapeutics' stock symbol?

Novus Therapeutics trades on the NASDAQ under the ticker symbol "NVUS."

What is Novus Therapeutics' stock price today?

One share of NVUS stock can currently be purchased for approximately $1.37.

How much money does Novus Therapeutics make?

Novus Therapeutics (NASDAQ:NVUS) has a market capitalization of $1.97 million. The biopharmaceutical company earns $-16,010,000.00 in net income (profit) each year or ($21.58) on an earnings per share basis.

How can I contact Novus Therapeutics?

Novus Therapeutics' mailing address is 19900 MACARTHUR BOULEVARD SUITE 550, IRVINE CA, 92612. The official website for the company is novustherapeutics.com. The biopharmaceutical company can be reached via phone at 949-238-8090 or via email at investors@novustherapeutics.com.

This page (NASDAQ:NVUS) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -